Biologics are increasingly used in the treatment of inflammatory bowel disease (IBD), but real-world data quantifying the costs of these therapies have been lacking. A new study, published in Alimentary Pharmacology and Therapeutics, sought to determine trends in costs and relative market share of IBD therapies in the United States over the past 9 years.
Biologics are increasingly used in the treatment of inflammatory bowel disease (IBD), but real-world data quantifying the costs of these therapies have been lacking. A new study, published in Alimentary Pharmacology and Therapeutics, sought to determine trends in costs and relative market share of IBD therapies in the United States over the past 9 years.
Drawing from de-identified outpatient, inpatient, and pharmaceutical claims for approximately 40 million to 50 million patients in the Truven MarketScan Commercial Claims and Encounters database for the years 2007 to 2015, the researchers included patients with IBD diagnoses and at least 1 pharmaceutical claim during the study period.
The study cohort comprised 415,405 patients; 188,842 patients had Crohn’s disease (CD), 195,183 patients had ulcerative colitis (UC), and 31,380 patients had indeterminate colitis (ID). During the 9-year period, among patients with CD:
In patients with UC:
Patients who used corticosteroids only remained largely stable in both populations (CD: 16.9% versus 16.6%; UC: 18.8% versus 16.2%).
Utilization trends show a consistent rise in biologics’ market share; from 2007 to 2015, use of biologic therapies increased from 13.7% to 30.1%. A pediatric subgroup analysis showed an even sharper rise in biologics use, from 19.1% in 2007 to 45.9% in 2015.
The cost of biologic therapy also rose over the study period; in 2007, the average patient taking biologic therapy accounted for $25,275 in per-member per-year costs (a value comprising the costs paid by a patient's health plan plus the patients’ copay and deductible amounts). In 2015, that amount rose to $36,051. Pediatric patients’ costs grew even more, from an average $23,616 to $41,109. These cost trends for biologics “greatly exceed” the cost trends for other drugs that treat IBD, including immunomodulators, 5-ASAs, or corticosteroids.
“From a clinician perspective, corticosteroid-sparing therapy plans are evidence-based and necessary to optimize long-term health outcomes, maximize quality of life, and minimize opportunity loss,” the authors write. However, the increases in cost associated with biologic therapies are only expected to continue for US patients with IBD. “The findings from our study further reiterate the ongoing need to develop patient-centered, cost-effective pharmacotherapy strategies by judiciously incorporating biologics in individualized therapy plans.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.